GlassScriptPhysician profile
Lara White
NPI 1801608252
$932.86
in general payments reported to CMS, 2019-2025
15 companies · $933 in 2025
The $933 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909 · Consulting Fee: $23.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.91 |
| Consulting Fee | $23.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $191.79 | 2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $87.28 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $87.27 | 2025 | Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $80.78 | 2025 | Cuvitru, Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $80.38 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $73.62 | 2025 | Dupixent |
| Lilly USA, LLC | $66.14 | 2025 | Ebglyss, Taltz |
| Genzyme Corporation | $63.93 | 2025 | |
| Biocryst US Sales Co., LLC | $52.51 | 2025 | Orladeyo |
| Arcutis Biotherapeutics, INC. | $43.91 | 2025 | Zoryve |
| Pharming Healthcare, INC. | $26.50 | 2025 | Ruconest |
| Adma Biomanufacturing LLC | $23.95 | 2025 | |
| Glaxosmithkline, LLC. | $23.13 | 2025 | Trelegy Ellipta |
| Csl Behring | $22.04 | 2025 | Hizentra |
| Organon LLC | $9.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.